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Distal myopathies are a heterogeneous group of disorders characterized by progressive weakness and muscular atrophy, be-
ginning in distal limb muscles and affecting proximal limb muscles at a later stage. We studied a large German kindred with 10
affected members. Weakness and atrophy of the anterior tibial muscles started between the ages of 8 and 16 years, followed by
atrophy of intrinsic hand muscles. Progression was slow, and patients retained the ability to walk until the seventh decade.
Serum creatinine kinase levels were increased in the range of 150–1400U/l. Muscle biopsies showed myopathic changes,
whereas immunohistochemistry showed normal expression of marker proteins for muscular dystrophies. Patients had reduced
sensation with stocking-glove distribution in the distal limbs in later life. Nerve conduction studies revealed no evidence of
neuropathy. Genome-wide linkage analysis in this family revealed a new locus for distal myopathy at 9p21.2-p22.3 (multipoint
logarithm of the odds ratio=4.21). By positional cloning we found a heterozygous mutation L95F in the Kelch-like homologue 9
gene, encoding a bric-a-brac Kelch protein. Molecular modelling indicated that the mutation may interfere with the interaction
of the bric-a-brac domain with Cullin 3. Coimmunoprecipitation experiments conﬁrmed that the mutation reduces association
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protein degradation. We identiﬁed a unique form of early onset autosomal dominant distal myopathy which is associated with a
Kelch-like homologue 9 mutation and interferes with normal skeletal muscle through a novel pathogenetic mechanism.
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Introduction
Distal myopathies form a heterogeneous group of disorders char-
acterized by progressive muscular atrophy and weakness, begin-
ning in distal and proceeding to proximal limb muscles. Age at
onset, inheritance pattern and clinical as well as histopathological
features have been used to distinguish different forms with linkage
to different genetic loci or genes. The autosomal dominant in-
herited distal myopathies are: (i) Welander myopathy, a late
adult onset myopathy (MIM 604454) with clinical onset in the
hands and linkage to chromosome 2p13 (Ahlberg et al., 1999);
(ii) Udd distal myopathy (MIM 600334), which starts with weak-
ness in the anterior compartment of the lower leg and is caused by
mutations in the Titin (TTN) (MIM 188840) gene (Haravuori
et al., 2001; Hackman et al., 2002); (iii) the late adult onset
zaspopathy (Markesbery–Griggs) caused by mutations in the LIM
domain binding 3 ZASP (MIM 605906) gene (Griggs et al., 2007),
which begins after 40 years of age with ankle dorsiﬂexion weak-
ness, progressing to ﬁnger and wrist extensors; (iv) a new adult
onset form caused by mutations in Matrin3 (MATR3) has recently
been described (Senderek et al., 2009). A distinguishing feature of
MATR3 mutations is vocal cord paralysis and pharnygeal weakness
but these were not present in all affected family members; (v)
early adult/infantile onset Laing myopathy (MIM 160500),
which starts in the anterior compartment of the lower leg,
shows autosomal dominant inheritance and is caused by mutations
in the tail of myosin heavy chain 7 (MYH7) (MIM 160760) gene
located at chromosome 14q11 (Laing et al., 1995; Voit et al.,
2001; Meredith et al., 2004); and (vi) Mahjneh et al. (2003) re-
ported a distal myopathy from Finland (MIM 610099) with adult
onset and rimmed vacuoles, which showed signiﬁcant linkage to
two separate loci, 8p22-q11 and 12q13-q22 (Mahjneh et al,
2003; Haravuori et al., 2004). The autosomal recessively inherited
types include: (i) early onset Nonaka myopathy (MIM 605820),
which starts with onset in the distal legs. Mutations in the
UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine
kinase (GNE) (MIM 603824) gene on chromosome 9p12-p13
are associated with the hereditary inclusion body myopathy
(Eisenberg et al., 2001) (MIM 600737) and are also described in
Nonaka myopathy (Kayashima et al., 2002); (ii) early adult onset
Miyoshi myopathy (MIM 254130), which affects calf muscles, is
caused by mutations in the Dysferlin gene (MIM 603009) on
chromosome 2p13 (Liu et al., 1998; Aoki et al., 1999) and is
allelic to limb girdle muscular dystrophy 2B (MIM 253601); and
(iii) homozygous missense mutations in the Nebulin (NEB) gene
which cause childhood to early adulthood onset distal myopathy
with ankle dorsiﬂexor, ﬁnger extensor and neck ﬂexor weakness
(MIM 161650). The progression is mild, and the patients remain
ambulant (Wallgren-Pettersson et al., 2007).
Furthermore, families with uncomplicated distal myopathy but
without a known genetic cause have been reported (Udd, 2007,
2009), and several reports describe families with distal myopathy
associated with features such as joint contractures and kyphosco-
liosis (Bautista et al., 1978), external ophthalmoplegia, weakness
of pharynx muscles and respiratory failure (MIM 607569) (Uyama
et al., 1998). Interestingly, a family with adult onset dominant
distal vacuolar myopathy with additional features including dys-
phonia, dysphagia, pes cavus and areﬂexia was mapped to
chromosome 19p13.3 (Servidei et al., 1999). This locus has been
further conﬁrmed in a family with autosomal dominant distal my-
opathy, but the additional clinical features were less striking
(Di Blasi et al., 2004).
The myoﬁbrillar myopathies are an important differential diag-
nosis, e.g. the above mentioned zaspopathy, and other gene mu-
tations such as in the Desmin and Myotilin genes, which mainly
present as a distal myopathy (Udd, 2007, 2009).
Here, we describe a novel form of early onset distal myopathy
with autosomal dominant inheritance in a large German family.
Affected family members developed mild sensory disturbances in
stocking-glove distribution later in life, a distinguishing feature for
distal myopathy. We mapped the disease to a new locus on
chromosome 9p21.2-p22.3. Screening of candidate genes resulted
in the identiﬁcation of a heterozygous missense mutation
c.796T4C (NM_018847.1) leading to a p.L95F mutation in the
kelch-like homologue-9 (KLHL9) gene, which segregated with the
disease phenotype. Molecular modelling and immunoprecipitation
studies showed that the mutation reduces interaction with Cullin 3
(Cul3) in the KLHL9–Cul3–Roc1 E3 ubiquitin ligase complex.
Materials and methods
Patients and clinical evaluation
We studied four generations of a German family with distal myopathy
(Fig. 1). Ten affected members, three unaffected members and two
with unclear status from three generations were examined physically,
while the remaining family members were contacted by phone. The
muscle biopsies were obtained from the index patient (950307) at the
age of 17 years from the gastrocnemius muscle during an Achilles
tendon release surgery, and at the age of 32 years from the vastus
lateralis muscle via Bergstro ¨m needle. The biopsy specimens were pro-
cessed in the neuropathology laboratory using standard protocols for
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staining. Immunhistochemistry of muscle sections were performed as
described elsewhere (Herrmann et al., 2000). The study was approved
by the Ethical Review Board of the University of Essen. Informed con-
sent was obtained from all family members.
Analysis of linkage with known distal
myopathy loci
DNA was isolated from peripheral lymphocytes using standard proto-
cols. For exclusion of previously described loci for distal myopathy we
used the following polymorphic microsatellite markers: locus 2p12-p14
(Miyoshi myopathy and Welander myopathy): D2S303, D2S292,
D2S291, D2S169 and D2S329; locus 2q31-q33 (Udd myopathy):
D2S138, D2S148, D2S300, D2S385, D2S324, D2S2310, D2S1391,
D2S152, D2S389 and D2S315; Locus 9p12-p13 (Nonaka myopathy):
D9S43, D9S248, D9S165 and D9S50; and locus 14q11 (Laing
myopathy): D14S72, D14S283, D14S50, MYH7, D14S64, D14S54
and D14S49. Polymerase chain reactions (PCRs) were performed with
ﬂuorescent end-labelled microsatellite markers and semi-automated
genotyping was performed on an ABI 377 (Applied Biosystems)
Sequencer using the Genotyper V 3.7 (Applied Biosystems) software.
Genome scan
The genome scan was performed using the core pedigree shown in
Fig. 1. We performed a genome-wide scan with 439 microsatellite
markers that had an average marker density of 7.76 3.80cm
(Marshﬁeld) (Hoffmann et al., 2007). PCRs of ﬂuorescent labelled
microsatellite markers were performed as described elsewhere (Thiele
et al., 2004). The genotyping was done by a MegaBACE-1000
(Amersham) analysis System using the Genetic Proﬁler Software 1.5
(Amersham). PedCheck (O’Connell and Weeks, 1998) was used for
detection of Mendelian errors. The correct relationships in families
were conﬁrmed by the program Graphical Relationship
Representation (Abecasis et al., 2001). Two-point linkage analyses
were performed using the software FASTLINK v4.1 (Cottingham
et al., 1993), multipoint linkage analyses using Genehunter v2.1
(Kruglyak et al., 1996) and Simwalk v2.86 (Sobel and Lange, 1996).
We assumed an autosomal-dominant model with 100% penetrance,
equally distributed alleles and a disease allele frequency of 0.0001.
Haplotype reconstruction was done by Simwalk2 v2.86 and
Genehunter v2.1. The ﬁne mapping was performed using the ex-
tended pedigree shown in Fig. 3B. Subsequent ﬁne mapping included
markers D9S274, D9S156, D9S1778, D9S161 and D9S270.
Sequencing of candidate genes and
mutational analysis of KLHL9
The following genes were chosen as candidate genes according to
NCBI Human Genome draft number 35: ADAMTSL (a disintegrin
and metalloproteinase with thrombospondin motif-like), KIAA1354
(KLHL9), FLJ39267, TEK (endothelial tyrosine kinase) and CCDC2
(coiled coil domain containing 2). Based on the predicted and anno-
tated sequences, primers pairs were designed using the Primer 3 pro-
gram (Rozen and Skaletsky, 2000) (primer sequences used available on
request). All coding exons with exon-intron boundaries were ampliﬁed
from genomic DNA and both strands of the PCR products were
sequenced using Big-Dye Terminator 1.1 (Applied Biosystems) on an
ABI 3730xl sequencer (Applied Biosystems). We performed sequence
comparisons using the DNASTAR package (Lasergene). Mutations
indentiﬁed in the KLHL9 gene were conﬁrmed by restriction enzyme
digestion with Hind III (Fermentas) with the following primer pair:
primer A (forward) CCCTTGATAAGGAAACGAGC, primer B (reverse)
TGTTAGCAATTCGTCCAACC, which yielded a 602bp product. PCR
fragments containing the wild-type sequence had two restriction
Figure 1 Pedigree. Circles denote females, squares denote males, slashed symbols indicate death, ﬁlled symbols indicate the diagnosis of
distal myopathy. The index patient is indicated with a red arrow. The symbols ﬁlled with grey colour and a question mark indicate that the
affection status of these family members could not be identiﬁed because of either death or that, at the age of examination, they were
considerably younger than the age of onset. All family members with a six-digit identiﬁcation number were genotyped. This shows the
pedigree that was used for the exclusion of distal myopathy loci and the genome scan.
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mutation KLHL9 abolishes the last restriction site and results in four
digestion fragments of 106, 207, 289 and 496bp in the heterozygous
patients.
Reverse transcriptase polymerase chain
reactions
The tissue expression patterns of KLHL9 (NM_018847) and b-actin
(NM_001101) as a control (NM_001101) were examined by reverse
transcriptase polymerase chain reaction (RT-PCR) using a human 24
tissue rapid-scan cDNA panel (HSCA101; OriGene) with the following
PCR primers:
KLHL9—FOR 2146 50-GACCCCAATTGCCGCCATGTTA-30;
KLHL9—REV—2340 50-CAGGCTCGAATGCCACCAAGTG-30;
-actin—FOR 736 50-GGACTTCGAGCAAGAGATGG-30;
-actin—REV 969 50-AGCACTGTGTTGGCGTACAG-30.
Each 25ml PCR reaction consisted of: 2.5ml1 0   PCR buffer, 1pmol
forward primer, 1pmol reverse primer, 1.25ml 1mM deoxynucleoside
triphosphates, 1.5mM MgCl2 and ﬁve units of Taq polymerase
(Invitrogen, USA). The PCR conditions followed the manufacturer’s
recommendations: one cycle at 94 C for 3min; 35 cycles at 94 C
for 30s, 55 C for 30s, 72 C for 2min; one cycle at 72 C for 5min;
4 C hold. RT-PCR primers were designed using Primer3 (Rozen and
Skaletsky, 2000). The products were resolved by agarose gel electro-
phoresis, visualized on an ultraviolet transilluminator and the images
captured using a charge-coupled device camera system (Fotodyne Inc.,
USA). The expression levels of KLHL9 and b-Actin in each tissue type
were quantiﬁed with MultiGauge v. 2.3 (Fujiﬁlm Medical Systems,
USA) and the ratios of KLHL9:b-actin expression were calculated
and normalized to the expression levels of KLHL9 and b-actin in
muscle tissue, which was assigned a value of ‘1’, as shown in
Supplementary Table 1.
Molecular modelling
The structural model of the bric-a-brac (BTB)–Cul3 complex was gen-
erated through superposition of the Skp1–Cul1 domain (Protein Data
Bank id: 1ldj) (Zheng et al., 2002) and the promyelocytic leukemia zinc
ﬁnger protein BTB domain (Protein Data Bank id: 1buo) (Ahmad et al.,
1998) crystal structures (Stogios et al., 2005). Molecular modelling
and illustrations were generated with PyMOL (DeLano Scientiﬁc)
(DeLano, 2003). The location of the KLHL9 p.L95F mutation within
the complex was identiﬁed by a sequence alignment of the BTB
domains from promyelocytic leukemia zinc ﬁnger protein and KLHL9.
Expression vectors
The expression vector for human inﬂuenza hemagglutinin (HA) Tag-
cullin 3 (HA-Cul3) has previously been described (Zhang et al., 2004).
The cDNA for human KLHL9 (KIAA1354) was obtained from the
Kazusa DNA Research Institute (Chiba, Japan) and sequenced to con-
ﬁrm its identity. The p.L95F amino-acid substitution was introduced
with overlapping primers via a PCR-based approach with Pfu Turbo
polymerase (Stratagene). For cloning purposes, ﬂanking BamHI and
XhoI restriction sites were introduced by PCR with Pfu Turbo polymer-
ase (Stratagene). To express wild-type or L95F mutant KLHL9 as
N-terminal FLAG epitope-tagged proteins in mammalian cells, the
cDNAs encoding wild-type KLHL9 and mutant L95F KLHL9 were
cloned in frame into the pCMV-Tag2A expression vector
(Stratagene). The wild-type and mutant p.L95F KLHL9 cDNAs were
cloned into the BamHI and XhoI sites of pCMV-Tag2A (Stratagene).
The integrity of the entire coding region of both wild-type and p.L95F
KLHL9 were veriﬁed by sequence analysis.
Human embryonic kidney 293T cell
culture and transfections
Human embryonic kidney 293T cells (ATCC CRL-11268) were cultured
in a humidiﬁed 37 C, 5% CO2 incubator on 0.1% gelatine-coated
tissue culture dishes in high glucose (4.5g/l) Dulbecco’s modiﬁed
Eagle’s medium supplemented with 2mM L-glutamine, 10%
heat-inactivated foetal bovine serum, amphotericin and gentamycin.
For transfections, 9 10
5 human embryonic kidney 293T cells were
seeded onto 0.1% gelatine-coated 60mm tissue culture dishes on the
day prior to transfection. Each 60mm dish of human embryonic kidney
cells was re-fed with 2ml of Dulbecco’s modiﬁed Eagle’s medium
lacking any additives and transfected with 3mg of total plasmid DNA
comprised of 750ng of wild-type or p.L95F KLHL9 and either 0, 83.3,
250, 750 or 2250ng of HA-Cul3 and empty pcDNA3.1 (Invitrogen)
vector up to 3mg total with 8 ml PLUS reagent (Invitrogen) and 12ml
Lipofectamine (Invitrogen) in the 37 C, 5% CO2 incubator. After a 4h
incubation period, the cells were re-fed with complete Dulbecco’s
modiﬁed Eagle’s medium and returned to the 37 C, 5% CO2 incuba-
tor. Expression of the HA-Cul3, wild-type and p.L95F FLAG-KLHL9
constructs was conﬁrmed by immunoblot analysis.
Immunoprecipitations and immunoblots
At 40h post-transfection, the transfected cells were washed with cold
1  phosphate buffered saline (pH 7.4) and cell lysates were collected
in erythrocyte lysis buffer (50mM HEPES, pH7.4, 250mM NaCl, 5mM
EDTA, 0.1% Triton X-100) supplemented with 1mM dithiothreitol,
1mM NaF, 0.4mM NaVO3, 1mM phenylmethanesulphonyl ﬂuoride
and Protease Inhibitor Cocktail (Sigma) and clariﬁed by centrifugation
at 14000g for 10min at 4 C. Total protein concentration was deter-
mined by Bradford assay (Bio-Rad). Equivalent amounts of total pro-
tein were pre-cleared with protein A agarose (Sigma) for 1h on the
rotator at 4 C and subjected to overnight anti-FLAG M2 (F3165;
Sigma) immunoprecipitations at 4 C, on the rotator. The immunopre-
cipitates were collected with protein A agarose (Sigma), extensively
washed with erythrocyte lysis buffer, resolved by sodium dodecyl sul-
phate polyacrylamide gel electrophoresis, transferred to nitrocellulose
and subjected to rabbit anti-HA (Covance) immunoblot analysis using
the SuperSignal West Dura Extended Duration Substrate system
(Thermo Fisher Scientiﬁc) enhanced chemiluminescence system.
Images were captured using a charge-coupled device camera system
(Fujiﬁlm Medical Systems) and the expression levels of wild-type
FLAG-KLHL9, mutant FLAG-L95F-KLHL9 and HA-Cul3 were deter-
mined using MultiGauge v. 2.3 (Fujiﬁlm Medical Systems). The results
are shown in Supplementary Table 2.
Results
Family and index patient
The pedigree encompassed 33 family members from four gener-
ations and indicated a dominant inheritance (Figs 1 and 3B). The
family originated from the north of Germany. In total, 15 family
members underwent physical examination, 10 of whom were af-
fected. Two unaffected children were younger than the mean age
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was deﬁned as ‘unknown’ for linkage analysis.
First symptoms of weakness appeared between the ages of 8
and 16 years, resulting in difﬁculties in walking on heels, followed
by selective weakness and slow wasting of ankle extensors leading
to a high stepping gait. Progression of weakness was very slow.
The proximal muscle groups were generally spared. Common fea-
tures of the affected family members were ankle contractures,
reduced sensation in stocking distribution in lower limbs and
weakness in intrinsic hand muscles. The ankle joint contractures
might be a secondary phenomenon to drop foot. Some affected
family members also had sensory symptoms in the hands. Nerve
conduction studies available in some patients did not conﬁrm a
deﬁnite peripheral neuropathy. The serum creatine kinase levels
were elevated and ranged between 200 and 1400 U/L. A sum-
mary of the clinical ﬁndings in other affected family members is
provided in Table 1. The index patient is the most severe case in
this family; all other affected family members have milder
difﬁculties.
The index patient (950307, Figs 1, 2 and 3) experienced
ﬁrst symptoms at the age of 12 years with foot drop, heel walk
difﬁculties and unsteady gait due to atrophy of anterior tibial
muscles. Clinical examination at the age of 16 years showed a
‘naked tibia’ with ankle contractures and distinct atrophy of
ankle extensors. Mild intrinsic hand muscle atrophy with formation
of a tabatie `re was noticed at the age of 16 years. At 17 years of
age, surgical lengthening of the right Achilles tendon was
performed.
Follow-up of the index patient at the age of 32 years showed
muscle wasting of the lower limb muscles in particular the tibialis
anterior muscles. Dorsal ﬂexion and inversion of the ankles were
not possible; ﬂexion and eversion were very weak. There was
moderate weakness of limb girdle muscles, particularly of the hip
extensors. Hopping on one leg was impossible. The patient was
still ambulant, with the use of callipers. Strength of proximal
muscle groups in the arms was normal. Impairment of sensation,
in particular touch and vibration, in the lower legs (up to the
knees) and in the hands was observed. There was a slight postural
tremor, and the intrinsic hand muscles showed weakness and at-
rophy. The Achilles and patellar muscle stretch reﬂexes could not
be elicited. Touch and vibration senses were reduced. Cranial
nerve examination was normal. Echocardiography, electrocardio-
gram and lung function testing were normal.
Nerve conduction studies and
electromyography
Table 2 summarizes the results of nerve conduction studies per-
formed in two patients.
Few distal motor latencies were found to be increased. In one
study, the amplitude of the sural sensory nerve action potential
was reduced. All other nerve conduction velocities were within
normal limits.
An electromyography of anterior tibial, gastrocnemius and inter-
osseus I dorsalis muscles in Patient 950307, performed at 14 years
of age, revealed signs compatible with active denervation with
ﬁbrillation potentials and positive waves, as well as chronic neuro-
genic alteration most pronounced in lower limbs. Motor unit po-
tentials were strikingly polyphasic, and recruitment of motor unit
potentials was mildly reduced in the interosseus I dorsalis muscle
and markedly reduced in tibial and gastrocnemius muscles. These
changes might be partly secondary to myopathy and do not prove
a peripheral neuropathy.
Table 1 Clinical details of the affected individuals
Patient ID Age at
examination
(years)
Age of
onset
(years)
Atrophy of
anterior
tibial
muscles
Contractures
of ankles
Reduced
sensation
Weakness of
intrinsic
hand muscles
CK (U/l) Other features
950202 63 ? + + Lower leg, hand + 170 Reduced motor nerve
conduction velocity of
peroneal nerve (39m/s)
950206 67 ? + + Lower and upper leg,
hand
+ 200 Deep tendon reﬂexes in legs
not preserved
950302 40 16 + + Lower leg, hand   110
950304 39 10 + + Lower leg + 190
950306 34 13   (+) Lower leg (+) 260 Reduced amplitude 5.7mV
and increased distal motor
latency with 6.9ms of
peroneal nerve with 51m/s
950308 25 13 + + Lower leg, hand + 140
950307 25 8 + + Lower leg, hand + 700–1400 Deep tendon reﬂexes in legs
reduced, surgical lengthen-
ing of the right tendon
Achilles at age 17 years
Peripheral axonal
neuropathy
950402 18 16   (+)    170
950405 12 10 + (+)    230
Patient ID according to pedigree in Fig. 1.
Distal myopathy KLHL9 Brain 2010: 133; 2123–2135 | 2127Figure 2 Clinical information from index Patient 950307. (A) Index patient at the age of 16 years, clearly with atrophy of anterior tibial
muscles. (B) Index patient at the age of 32 years with the sign of the ‘naked tibia’ due to distal atrophy. (C) Axial T1-weighted spin echo
images (Magnetom Symphony, Siemens, FGR: 1.5 Tesla system, repetition time of 377ms, echo time 20ms, two acquisitions, 10mm slice
thickness, ﬁeld of view of 300 300mm) showing the muscle MRI of distal thigh (I) and proximal lower limb (II). In the lower thigh,
striking changes are evident in the semimembranosus, biceps femoris and vastus intermedius muscles. Fatty atrophy in the lower leg was
pronounced in the tibialis anterior, gastrocnemius and soleus muscles with relative preservation of tibialis posterior and peroneus longus
muscles. (D) Trichrom stain of the muscle biopsy from the gastrocnemius muscle at the age of 15 years showing a myopathic pattern with
variation ﬁbre size, atrophic ﬁbres, replacement by fat and connective tissue and internal nuclei. Furthermore some peripheral nerves are
visualized, which show normal myelinization. (E) Haematoxylin-eosin stain of the vastus lateralis muscle at the age of 32 years conﬁrming
the myopathic features and (F) the nicotinamide adenine dinucleotide stain of the same biopsy showing a loss of ﬁbre typing. All images
were captured with 20  objective lens.
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of age)
The muscle MRI (Fig. 2C) with T1 images of the lower limbs
showed symmetric fatty atrophy of muscles. In the lower thigh,
the most signiﬁcant changes were seen in the semimembranosus
muscle, in the biceps femoris muscle as well as in the vastus
intermedius muscle, whereas the lateral and medial vastus muscles
and parts of the adductor muscles gracilis and sartorius were pre-
served. Fatty atrophy of the lower leg was pronounced in the
tibialis anterior, gastrocnemius and soleus muscles with relative
preservation of the tibialis posterior and peroneus longus muscles
(Fig. 2C).
Muscle biopsy (Patient 950307)
A muscle biopsy of the gastrocnemius muscle, taken at age
17 years, showed an increased variation in ﬁbre size with atrophy
and hypertrophy, disseminated atrophic ﬁbres, replacement of
muscle by fat and connective tissue, and an increase of
Figure 3 Whole genome scan and haplotypes of the disease locus at chromosome 9p21.2-p23.3. (A) Genome-wide two point LOD
scores are shown, one bar for every genotyped marker. The red bars indicated a maximum LOD score at recombination fraction =0. The
blue bars show markers with a positive LOD score with 40, the black bars stand for markers with negative LOD scores. The numbers of
the chromosomes are shown under the x-axis, the marker distances are drawn according to the DeCODE Map. (B) This ﬁgure shows the
haplotypes of the ﬁne mapping using the extended pedigree. Circles denote females, squares denote males, slashed symbols indicate
death, and ﬁlled symbols indicate the diagnosis of distal myopathy. The symbols ﬁlled with grey colour and a question mark indicate that
the affection status of these family members could not be identiﬁed because of either death or that at the age of examination, they were
considerably younger than the age of onset. All family members with a six-digit identiﬁcation number were genotyped. The haplotypes
were reconstructed using the Simwalk2 program. Uninformative or non-reconstructable markers are indicated with a black bar. The order
of the microsatellite makers are from p-telomer to centromer according to the DeCODE Map. The disease haplotype is marked with a
black square. Note that all affected family members carry the red haplotype. The index case is indicated with a red arrow.
Distal myopathy KLHL9 Brain 2010: 133; 2123–2135 | 2129internalized nuclei. No autophagic vacuoles or inclusions were seen
(Fig. 2D). A sural nerve biopsy, taken at 16 years of age, did not
show any signs of axonal or demyelinating neuropathy. A second
muscle biopsy of the vastus lateralis muscle, at 32 years of age,
showed myopathic changes with ﬁbre angulation and size vari-
ation, internal nuclei and increased connective tissue (Fig. 2E).
The NADH staining showed loss of ﬁbre typing and angulated
ﬁbres (Fig. 2F). As the vastus lateralis is less affected then distal
muscle groups, it may not show the full range of histopathological
changes. Immunocytochemistry showed normal expression of the
cell-surface proteins dystrophin, caveolin, laminin 2 and of the
dystroclycan-sarcoglycan complex (data not shown).
Linkage analysis
Previously described loci for autosomal dominant distal myopathy
on chromosomes 2p12-p14 (Miyoshi- and Welander-myopathy),
2q31-q33 (Udd-myopathy), 9p1-q1 (Nonaka-myopathy) and
14q11 (Laing-myopathy) were excluded by haplotype reconstruc-
tion and did not show evidence for linkage [logarithm of the odds
ratio (LOD)5 2]. Therefore, we performed a genome wide link-
age scan and subsequently identiﬁed a single disease region with a
maximum two-point parametric LOD=3.69 (D9S1870) at =0
(Fig. 3A, Table 3). Further ﬁne mapping with an extended pedi-
gree, with additional 10 markers, conﬁrmed the locus at
9p21.2-p22.3 with a multipoint LOD=4.21 within the interval
between D9S1870 and D9S161 (Supplementary Fig. 1).
Haplotype analysis revealed critical recombination events in the
affected individuals 950322 (proximal border) and 950304
(distal border), deﬁned D9S274 and D9S270 as the outer border
markers of the disease haplotype (Fig. 3B) and comprised 22.59
cM according to the DeCODE Map.
Candidate gene selection and
mutation analysis
For the positional cloning we used the NCBI Human genome Build
35 Version 1. At the time of analysis (August 2004), 81 genes
(including pseudogenes and predicted genes) were located be-
tween the Marker D9S274 and D9S270. Of these 81 genes, 19
were genes or pseudogenes for interferons, which we did not
consider as candidate genes, since the clinical and pathological
examinations did not suggest an inﬂammatory aetiology. The
locus contained 19 in silico predicted genes, and 9 transcripts
were pseudogenes. We prioritized the remaining 35 genes using
the following criteria: (i) expression in skeletal muscle; (ii) sharing
of homology and/or functional domains of the known genes for
distal myopathies: MYH7, GNE, TTN and dysferlin; (iii) structural
proteins of skeletal muscle; and (iv) evidence of a functional role in
skeletal muscle. A number of possible candidate genes were
Table 2 Nerve conduction studies
Motor conduction studies Sensory conduction studies
Age
(years)
Distal latency
(ms)
Conduction
velocity
(m/s)
Amplitude (mV) Age (years) Conduction
velocity (m/s)
Amplitude
(mV)
Patient 950307
Median R 14 4.8 41 n. a. Sural L 14 38 n.a.
Normal values
a [3.2 0.7] [49.6 3.4] [7.2 1.6] Normal values
a [40.6 4.8] [18.7 4.4]
Peroneal L 14 5.8
b 44 n. a. Sural L 31 60 6.9
Normal values
a [3.2 0.7] [49.6 3.4] [7.2 1.6] Normal values
c [47.0 4.6]
(35.8–62.0)
[17.2 10.1]
(1.7–67.3)
Peroneal L and R 31 n.o. n.o. n.o.
Tibial L 31 3.7 55 11.8
Tibial R 31 4.5 55 9.7
Normal values
b [4.5 0.8]
(3.2–6.9)
[47.0 5.4]
(32.7–61.0)
[11.0 5.2]
(0.3–25.6)
Patient 950306
Peroneal L 34 6.9
b 51 5.7 Sural L 34 53 13.8
43 5.6 59 5.5 43 55 18.6
Normal values
c [4.6 0.7]
(3.5–6.4)
[48.6 5.1]
(32.4–59.6)
[5.6 2.6]
(0.1–12.3)
Normal values
c [47.0 4.6]
(35.8–62.0)
[17.2 10.1]
(1.7–67.3)
Tibial L 43 4.6 60 35.1 Median L 43 62 34.6
Normal values
c [4.5  0.8]
(3.2–6.9)
[47.0 5.4]
(32.7–61.0)
[11.0 5.2]
(0.3–25.6)
Normal values
c [52.0 5.3]
(35.4–65.0)
[32.9 17.6]
(3.1–86.0)
Median L 43 3.8 52 18.4 Ulnar L 43 53 47.6
Normal values
c [3.6 0.6]
(2.4–5.9)
[56.0 3.9]
(43.8–63.5)
[9.1 3.3]
(1.7–19.5)
Normal values
c [52.4 4.1]
(40.3–62.9)
[29.8 17.6]
(4.4–90.7)
L=left; R=right; Amplitude=amplitude of compound muscle action potential; n.a.= not available; n.o =not obtained. Normal values are presented as mean   SD (range).
All the reference values and the range are in italics.
a Normal values from Cai and Zhang (1997).
b  2 SD from control (increase for distal latencies).
c Normal values from Benatar et al. (2009).
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which is essential for muscle integrity, as exempliﬁed by congenital
muscular dystrophy resulting from mutations in collagen VI alpha
chains. FLJ39267 contains a myosin tail, and coiled coil domain
containing two has 24% homology to the myosin heavy chain.
Mutations in the myosin heavy chain 7 tail cause Laing type distal
myopathy (Meredith et al., 2004). Endothelial tyrosine kinase con-
tains ﬁbronectin type III domains similar to titin (Hackman et al.,
2002), which if mutated causes distal myopathy type Udd. Finally,
KLHL9 was selected as candidate gene because it contains six
kelch domains that function as oligomeric ring canal actin organ-
izers in Drosophila (Robinson and Cooley, 1997). KLHL9 is also
expressed in skeletal muscle according to genetic databases such
as Genecards (http://www.genecards.org).
Sequencing coding exons and intron-exon boundaries of the
candidate genes ADAMTSL1, FLJ39267, TEK and CCDC2 did
not reveal any mutation. In contrast, a heterozygous missense
mutation was detected in KLHL9, c.796T4C (NM_018847.1),
leading to a leucine to phenylalanine substitution at amino-acid
position 95, situated in the conserved BTB-domain of the KLHL9
protein. This mutation co-segregated with the disease phenotype
as shown in Supplementary Fig. 2 and was not observed in 300
healthy unrelated German control individuals.
Alignment of Kelch proteins
KLHL9 is widely distributed across the vertebrates, and genes
encoding proteins with 490% sequence identities with human
KLHL9 are present in mammalian, ﬁsh and bird genomes
(Fig. 4D). All of the putative vertebrate KLHL9 orthologues have
a leucine at the equivalent position of Leu-85 in KLHL9. Within
the human genome, there are 49 BTB-BACK-Kelch (BBK) proteins
and KLHL9 is a typical representative of this group (Stogios and
Prive, 2004; Stogios et al., 2005). The residue position equivalent
to Leu-95 in KLHL9 is conserved in the human BBK proteins, and
is typically a leucine, isoleucine or methionine. The homologous
position in other family members (Fig. 4C, red box) also shows a
high propensity for large, aliphatic amino acids.
Molecular modelling
Modelling studies were used to predict the effects of mutation on
KLHL9 function. KLHL9 binds to Cul3 via its BTB-domain in the
KLHL9–Cul3–Roc1 E3 ubiquitin ligase complex (Furukawa et al.,
2003). The homology-based molecular model of the KLHL9/Cul3
complex places residue L95 of KLHL9 near the intermolecular
interface with Cul3 (Fig. 4A). Although L95 does not make
direct contact with Cul3 and is mostly buried within the BTB
domain, this residue is in close proximity of the Cul3 chain, and
replacement of an aliphatic residue with a large aromatic residue
at this position would probably affect the conformation of the BTB
domain, suggesting that the p.L95F mutation could disrupt the
KLHL9/Cul3 complex.
Functional analyses
As the p.L95F mutation resides within the BTB domain of KLHL9,
we hypothesized that the p.L95F amino-acid substitution reduces
association with Cul3. To determine whether the p.L95F mutation
within the BTB domain of KLHL9 disrupts association with Cul3,
we transfected human embryonic kidney 293T cells with mamma-
lian expression vectors for FLAG epitope-tagged wild-type or
p.L95F mutant KLHL9 and increasing amounts of HA-Cul3. The
expression levels of HA-Cul3 (Fig. 5A, middle panel) and either
wild-type FLAG-KLHL9 (Fig. 5A, lower panel, lanes 1–6) or
mutant FLAG-KLHL9-L95F (Fig. 5A, lower panel, lanes 7–11)
were conﬁrmed by total -HA and -FLAG immunoblots of total
lysates, respectively. Our results indicate that while the p.L95F
mutation does not alter the total levels of KLHL9, the p.L95F
mutation inhibits association with Cul3 (e.g. compare lanes 5–10
and 6–11).
Expression proﬁling
To examine the tissue distribution of KLHL9, we performed
RT-PCR on a human tissue cDNA panel. KLHL9 was expressed
in skeletal muscle and multiple tissues at moderate to high levels
with the exception of liver, colon, small intestine, the thyroid
Table 3 Two point LOD scores generated at various recombination fractions (h=0–0.4) for the marker in the region
9p22.3-p21.2
Marker cM
a 0 0.001 0.01 0.05 0.1 0.15 0.2 0.3 0.4
D9S269 24.29  1  4.842  1.889  0.006 0.62 0.861 0.936 0.828 0.504
D9S274 30.24  4.292  3.183  1.85  0.699  0.258  0.057 0.042 0.094 0.055
D9S156 34.03 2.873 2.87 2.844 2.707 2.501 2.263 1.996 1.388 0.704
D9S925 36.75 3.458 3.452 3.397 3.148 2.824 2.485 2.13 1.372 0.589
D9S1778 41.44 0.32 0.319 0.311 0.273 0.227 0.184 0.142 0.069 0.017
D9S1870 43.44 3.694 3.688 3.629 3.361 3.012 2.645 2.259 1.425 0.554
D9S1121 46.6 2.185 2.179 2.128 1.897 1.598 1.289 0.973 0.37  0.003
D9S169 49.65 2.216 2.212 2.179 2.026 1.826 1.615 1.391 0.906 0.395
D9S161 51.5 2.197 2.194 2.161 2.012 1.817 1.611 1.395 0.93 0.444
D9S270 52.79  1  0.859 0.104 0.634 0.72 0.677 0.583 0.341 0.128
D9S2149 53.59  1  1.745  0.719 0.038 0.338 0.467 0.515 0.469 0.292
a Marker position in cM refers to the DeCODE Map.
Distal myopathy KLHL9 Brain 2010: 133; 2123–2135 | 2131Figure 4 Structural model of the KLHL9–Cul3 complex and alignment of Kelch proteins. (A) The KLHL9 BTB homodimer is shown in light
blue/dark blue ribbons and the N-terminal region of Cul3 is shown as two green ribbons.The complex forms a dimer through
self-association of the BTB domain, and each BTB domain interacts with the N-terminus of one Cul3 molecule. The two L95 side chains
(circled) in the KLHL9 BTB dimer are in the vicinity of two equivalent and independent Cul3-binding interfaces.(B) Schematic
representation of the BTB-BACK-Kelch and Cul3 proteins in the context of a full-length, functional ubiquitin ligase complex. The red dots
indicate the approximate position of KLHL9 residue L95. (C) Multiple sequence alignment of the BTB domains from a representative subset
of the human BTB-BACK-Kelch proteins, including sequences from Val-65 to Thr-125 in KLHL9. The red asterisk denotes the position of
L95 in KLHL9. The homologous position in other family members (red box) shows a high propensity for large, aliphatic amino acids. The
blue bars indicate the level of conservation from dark blue (highly conserved) to light blue (less conserved). (D) Alignment of several
KLHL9 vertebrate proteins. The L95 residue is labelled with a red mark above and shows 100% conservation in vertebrates.
2132 | Brain 2010: 133; 2123–2135 S. Cirak et al.gland, pancreas and uterus, where KLHL9 was expressed at low
levels (Fig. 5B, Supplementary Table 1).
Discussion
In this report, we describe a family with a childhood onset dis-
tal myopathy with autosomal dominant inheritance. The pheno-
type bears similarities to the distal myopathy with childhood onset
previously described by Laing and Voit (Laing et al., 1995; Voit
et al., 2001; Mastaglia et al., 2002; Meredith et al., 2004; Lamont
et al., 2006). Patients with Laing myopathy also have onset of
muscle weakness in the anterior lower leg, followed by slowly
progressive weakness and involvement of proximal muscles. In
both disorders, weakness of ﬁnger extensors and hip extensors
followed many years later. In contrast to the Laing myopathy
phenotype, however, affected members of the family described
here did not demonstrate neck ﬂexor weakness or shoulder
girdle weakness. The early onset and the slow progression as
well as the distribution of affected muscles were also clearly dif-
ferent from the myopathies described by Welander, Markesbery–
Griggs, Udd, Nonaka and Miyoshi. Furthermore, the respective
loci for these and other relevant conditions were excluded by ex-
clusion mapping. The histopathological investigation of sural nerve
was normal at the age of 16 years for the index case, and
electrophysiological studies showed only minor abnormalities.
Clinical features including areﬂexia and sensory disturbances in
stocking-glove distribution in several family members were
distinctive.
A total genome scan identiﬁed the disease locus at
9p21.2-p22.3. A number of possible candidate genes were identi-
ﬁed in this interval but only the sequencing of the KLHL9 revealed
a mutation c.796T4C (NM_018847.1) leading to a p.L95F
amino-acid substitution in the conserved N-terminal BTB-domain,
which we consider to be pathogenic.
KLHL9 binds to Cul3 via its BTB domain to form an E3 ubiquitin
ligase complex (Furukawa et al., 2003). Interestingly, Cul3 is ex-
pressed in highest levels in skeletal muscle tissue (Du et al., 1998),
pointing to a myopathological effect of this mutation. The p.L95F
mutation is located in the conserved N-terminal BTB-domain of
KLHL9, and it is known that the deletion of the BTB-domain of
KLHL9 abolishes Cul3 binding (Furukawa et al., 2003). L95 is
located near the intermolecular interface with Cul3 (Fig. 4A). A
mutation at this position is likely to affect the conformation of this
region of the BTB domain. Indeed, pull-down assays revealed that
the p.L95F mutation diminishes association with Cul3 in vitro
(Fig. 5A). As mentioned above, KLHL9 forms a part of the
KLHL9–Cul3–Roc1 E3 ubiquitin ligase complex and functions as
a substrate adaptor that targets substrate proteins via its six
Kelch domains for ubiquitination by the KLHL9–Cul3–Roc1 E3 ubi-
quitin ligase (Furukawa et al., 2003). Hence, the targeted sub-
strates of KLHL9 for ubiquitination and later degradation by the
proteasome might accumulate, serving as a possible pathophysio-
logical mechanism of the distal myopathy in our patients. It has
Figure 5 Functional studies and expression. (A) The L95F mutation in KLHL9 reduces association with Cul3. Human embryonic kidney
293T cells were transfected with wild-type cytomegalovirus FLAG-KLHL9 (lanes 1–6) or mutant cytomegalovirus FLAG-L95F KLHL9
(lanes 7–11) and either 0ng (lanes 1, 2 and 7), 83.3ng (lanes 3 and 8), 250ng (lanes 4 and 9), 750ng (lanes 5 and 10) or 2250ng of
cytomegalovirus HA-Cul3 (lanes 6 and 11) expression vector. Cell lysates were collected at 40h post-transfection. Equivalent amounts of
total protein were immunoprecipitated with -FLAG antibody and subjected to an -HA immunoblot (upper panel). Total -HA (middle
panel) and -FLAG (lower panel) blots were conducted in parallel to conﬁrm the expression of the respective proteins. Our results clearly
demonstrate that the p.L95F mutation reduces association with Cul3 (compare lanes 5 to 10 and 6 to 11, for example). (B) KLHL9 is
expressed in multiple tissues. To examine the tissue distribution of KLHL9, a human cDNA panel was screened by RT-PCR. PCR products
were analysed on a 2% agarose gel. The results were conﬁrmed to be within the linear range by limited dilution of the cDNA products.
Quantiﬁcation of KLHL9 expression is shown in Supplementary Table 1.
Distal myopathy KLHL9 Brain 2010: 133; 2123–2135 | 2133recently been published that KLHL9 targets the Aurora B kinase on
mitotic chromosomes and regulates mitotic progression and com-
pletion of cytokinesis in human cells (Sumara et al., 2007). Aurora
B regulates the assembly and disassembly of type III intermediate
ﬁlaments including vimentin, desmin and peripherin as well as the
axonally expressed type IV neuroﬁlaments (Sihag et al., 2007).
The clinical pattern of distal myopathy and sensory disturbances
could be explained by the hypothetical interference of the KLHL9
mutation with the Aurora B kinase function, which is targeted for
degradation by KLHL9 (Sumara et al., 2007).
Our hypothesis of Aurora B kinase missregulation certainly
needs to be tested in further experiments. The homologue of
KLHL9 in the zebraﬁsh klhl and its human orthologue KLHL dis-
play conserved expression patterns in skeletal and cardiac muscles
(Wu and Gong, 2004). We did not ﬁnd clinical evidence of cardiac
involvement in this family. The facts and the course of the disease
in this family suggest that KLHL9 mutations primarily affect muscle
function, but it may be, to a lesser extent, important for the con-
servation of nerve function.
One possible pathophysiological mechanism may be the inter-
action between KLHL9 and Smad3 (Grimsby et al., 2004), which is
a myogenic transcription factor (Liu et al., 2001). The exact role of
KLHL9 in muscle and nerve homeostasis remains to be determined.
The KLHL9 protein belongs to the BTB-Kelch family of proteins
that includes gigaxonin, a protein which is mutated in
giant-axonal neuropathy (MIM 256550) (Bomont et al., 2000).
Gigaxonin controls the degradation of microtubule-associated pro-
tein 8 (MAP1B) and tubulin-binding cofactor B, and leads to a
neurodegenerative disorder of peripheral neuropathy due to im-
paired retrograde axonal transport and neuronal death (Ding
et al., 2006). The gigaxonin gene is as ubiquitously expressed as
the KLHL9 gene (Fig. 5B), and it causes a peculiar neurodegen-
erative disorder affecting the peripheral nerve and CNS. A muta-
tion in KLHL9 leads to distal myopathy with associated sensory
disturbances in several affected patients. Interestingly, several E3
ubiquitin ligases such as atrogin-1 and MuRF1 are markedly
up-regulated in muscle atrophy (Jackman and Kandarian, 2004).
Trim32, another ubiquitin ligase, is mutated in limb girdle muscular
dystrophy 2H (MIM 254110) (Kudryashova et al., 2005).
Identiﬁcation of targeted proteins of the KLHL9–Cul3–Roc1
complex may provide further understanding of the molecular
pathogenesis of KLHL9-related distal myopathies and also unravel
new candidate genes for distal myopathies. We did not ﬁnd
additional cases of KLHL9 mutations in a cohort of 20 cases
representing a broad spectrum of clinical presentations of distal
myopathy (data not shown). Further families and cases need to
be identiﬁed to understand the clinical spectrum of KLHL9
myopathy and the neurogenic component of this disease.
In conclusion, we report on a novel form of early onset auto-
somal dominant distal myopathy. This novel disorder is caused by
the heterozygous missense mutation p.L95F of KLHL9. KLHL9 is a
substrate adaptor of the Cul3–E3–ubiquitin ligase. The p.L95F mu-
tation is located in the conserved BTB domain of KLHL9, which
mediates interaction with Cul3, while the Kelch repeats mediate
association with substrates. We were able to demonstrate that the
mutation p.L95F diminishes the binding of KLHL9 to Cul3. The
KLHL9–Cul3–E3 ubiquitin ligase represents a novel pathway
leading to an early onset distal myopathy in contrast to the pro-
teins encoded by other mutated genes in distal myopathies: UDP-
N-acetylglucosamine 2-epimerase is an enzyme (Eisenberg et al.,
2001); dysferlin is a membrane protein (Liu et al., 1998); titin
(Hackman et al., 2002), nebulin (Wallgren-Pettersson et al.,
2007) and myosin heavy chain-7 (Meredith et al., 2004) are all
sarcomeric proteins (Udd, 2007). We propose that the distal
myopathy observed in this German family should be included in
the classiﬁcation schemes of distal myopathies as an early child-
hood onset distal myopathy, associated with mutations in the
KLHL9 gene.
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